A method for the analysis of one or more non-invasive sample biomarkers. Biomarkers within a normal concentration range may indicate not only the lack of disease, but also general health or lack of disease. These non-invasive sample biomarkers are corrected based on excretion of another non-invasive sample biomarker reflecting changes to the sample volume in a normal concentration range lacking disease. Method allows for indicating the existence of diseases, such as renal insufficiency, infections or other disease biomarkers by analyzing the concentration of biomarkers.

An electrochemically active device for collecting and retaining a biological sample with a bioanalyte, the device provided with at least a two-electrode member and an albumin-binding and an electrochemically active receptor in chemical contact with the two-electrode members and the biological sample. The present invention also provides a point-of-care biosensor with the device of the present invention and a method for measuring a bioanalyte in a biological sample. The device, point-of-care biosensor and the method of the present invention facilitate accurate measurements concentrations of urine albumin, human serum albumin (HSA), glycated albumin (GA) and methemalbumin (MHA) by determining redox current values in reduced volumes of biological samples.

There is provided a method for measuring an antigen, comprising: providing a solution containing an antigen; providing a first antibody that specifically recognizes the antigen and is bound to a magnetic carrier; providing a second antibody that specifically recognizes the antigen and is modified with an oxidase; providing (a substrate liquid including) a substrate which reacts with the oxidase; allowing the first antibody to recognize the antigen; allowing the second antibody to recognize the antigen; using a magnetic field to capture an antigen-antibody complex of the antigen recognized by the first antibody and the second antibody in the magnetic field; washing the antigen-antibody complex while it is captured in the magnetic field; reacting the substrate with the antigen-antibody complex to produce hydrogen peroxide; and measuring the hydrogen peroxide.

The present disclosure belongs to the field of application of protein, and relates to use of a protein in predicting properties of a drug. The drug comprises pesticides, human drugs and veterinary drugs, and the protein is applied in the following steps: preparing a 0.02 M phosphate buffer solution with pH value of 7.4; dissolving and diluting a protein solution with the prepared buffer solution according to a signal value to obtain a protein diluent; mixing the prepared protein diluent with the drug to be tested in a molar ratio of 1: (1-300) to obtain a mixed solution to be tested, and predicting the drug properties by using fluorescence spectrum, synchronous fluorescence, three-dimensional fluorescence, circular dichroism spectrum, UV-Vis absorption spectrum, linear spectrum or band spectrum.

This disclosure provides methods, systems, and compositions of matter for studying solvent accessibility and three-dimensional structure of biological molecules. A plasma can be used to generate marker radicals, which can interact with a biological molecule and mark the solvent-accessible portions of the biological molecule.

Determining the relative binding capacity of albumin (A), and amount of functional albumin, involves at least two measurement solutions of a test and reference sample. The measurement solutions contain an albumin-binding marker M. The marker in the measurement solution of the test and reference samples exceeds the presumed available albumin binding capacity. The test sample contains a defined amount of albumin of unknown binding capacity. The reference sample contains the same defined amount of albumin having a reference binding capacity. The measurement solutions are incubated under conditions that allow M:A complexes to form. The M:A complexes are removed. The presence or amount of unbound marker M in the solutions is detected after M:A complex removal by a test strip that allows determination of the unbound marker. The relative binding capacity of albumin in the test sample based on the presence or detected amounts of unbound marker is determined.

Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

The present invention is directed to a biosensor (10) having a photonic sensing device (20), a sheet of a porous material (60), and an optically clear cover layer (70). The optically clear cover layer (70) may be removable and replaceable, whereby the sheet of porous material (60) can be replaced, and the photonic sensing device (20) can be re-used. Detection devices (810, 910) that include the biosensor (10), as well as methods of making and using the biosensor (10) are also disclosed.

The present disclosure provides a healthcare management method comprising acquiring a first data that includes a glycoalbumin concentration and an albumin concentration in a body fluid from a subject; generating, on the basis of the first data, output information related to the GA value; and providing the generated output information to a user.

Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.